An interventional study of Statins (atorvastatin, rosuvastatin, simvastatin, or pravastatin), +/- ezetimibe, +/- PCSK9 inhibitor (alirocumab, evolocumab, inclisiran) in Melanoma, sponsored by University of Colorado, Denver. Recruiting at 1 site in United States. Open to participants aged 55 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.
Sponsored by University of Colorado, Denver · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 2,050 studies in Melanoma with a site in United States — 242 open to participants now, 437 under way, 32 of them phase 3. Melanoma · United States.
Among the 2,050 studies in Melanoma with a site in United States, this one is the 825th largest by planned enrollment of the 1,750 interventional ones that give a count, is one of 51 that started in 2026, is one of 159 with no phase, reaches primary completion later than 260 of the 432 other live ones, and was the 2,034th registered.
3,374 studies on the registry are indexed under Melanoma; 579 are open to participants now.
Browse Melanoma studies →242 of the 2,050 studies in Melanoma with a site in United States are open now. Recruiting first, the newest first:
Children's Oncology Group · Sites in United States
Ages up to 25
John Kirkwood · Sites in United States
Ages 18+
University of Wisconsin, Madison · Sites in United States
Ages 18+
H. Lee Moffitt Cancer Center and Research Institute · Sites in United States
Ages 18+ · Healthy volunteers
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 467 Melanoma studies recruiting now, 379 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.
This study: 55 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
2,050 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 934 · Phase 2 907 · Phase 3 115 · Phase 4 11
First in 1991; this study’s year is marked. 51 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is close to the median of 40 across 2,652 interventional studies indexed under Melanoma.
Median enrollment 37 across the 1,750 interventional studies, 156 across the 212 observational. Of the 1,485 that completed or were terminated, 598 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
801 of 2,050 have an industry lead sponsor. The 10 most frequent:
University of Colorado, Denver is the lead sponsor of 1,547 studies on the registry; 318 are open to participants now.
Of its 148 completed or terminated interventional studies of FDA-regulated products, 93 (63%) have results posted.
University of Colorado, Denver has 9 studies filed under Melanoma — fewer than ten, so there is no comparison to draw.
136 of the studies in Melanoma with a site in United States that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05608291Phase 3Regeneron PharmaceuticalsA Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery | 2027-01-15 |
| NCT05987332Phase 3IDEAYA BiosciencesIDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma | 2027-01-15 |
| NCT06246916Phase 3Regeneron PharmaceuticalsA Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head) | 2027-03-22 |
| NCT01223248Phase 3Memorial Sloan Kettering Cancer CenterRandomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy | 2027-10 |
| NCT06112314Phase 3Immunocore LtdIMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301) | 2027-10-16 |
Add all 136 to your calendar (.ics) → With an account.
Among the 2,050 studies in Melanoma with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Immune checkpoint inhibitors (ICIs) are a class of medications that are now standard in the treatment of melanoma. These are standard therapy for melanoma, but long-term side effects on disease in the heart arteries is poorly understood. In this study, melanoma patients receiving ICIs for the first time will undergo a coronary computed tomography angiography (CCTA) scan. CCTA results will be analyzed by the FDA-approved Cleerly TM image analysis pipeline. Patients with disease in their heart arteries will be randomized to usual care or aggressive lipid lowering therapy. Those in the aggressive lipid lowering therapy arm will be seen by a cardiologist and placed on standard lipid lowering medications with a goal of achieving an LDL-C ≤ 55mg/dL. Follow-up CCTA scans will occur at 12-month and 24-month timepoints. The primary outcome of interest will be differences in LDL-C levels between the two arms at the 12-month timepoint. The secondary outcome of interest will be the differences in total plaque volume between the two arms at the 12-month timepoint.
The criteria were revised on the registry on Nov 2, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Active Comparator: Usual Care: 12- and 24-month follow-up CCTA with plaque staging, lipid panel
Participants in the 'aggressive lipid lowering therapy' arm will receive guideline-directed lipid lowering therapy (statins and/or PCSK9 inhibitors) managed by a cardiologist. Dosing adjustments will be guided by individual patient response and standard-of-care practices, with the goal of achieving LDL-C ≤55 mg/dL.
Drug: Statins (atorvastatin, rosuvastatin, simvastatin, or pravastatin), +/- ezetimibe, +/- PCSK9 inhibitor (alirocumab, evolocumab, inclisiran)
Drug pages: StatinsStudies of StatinsStatins pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · EzetimibeStudies of EzetimibeEzetimibe pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · PCSK9 InhibitorStudies of PCSK9 InhibitorPCSK9 Inhibitor pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Participants randomized to the aggressive lipid lowering therapy arm will receive Guideline-directed lipid-lowering therapy (statins and/or ezetimibe and/or PCSK9 inhibitors) managed by a cardiologist with dose adjustments to achieve LDL-C ≤55 mg/dL.
Mean change in LDL-C from baseline to 12 months
Each participant will have LDL-C measured prior to randomization and at the 12-month timepoint. The mean change in LDL-C (mg/dL) from baseline to 12 months will be calculated for each participant. The mean change will be compared between the aggressive lipid-lowering therapy arm and the usual care arm.
Time frame: Baseline to 12 months
Change in Total Plaque Volume from Baseline to 12 months
Each participant will have total plaque volume measured prior to randomization and at the 12-month timepoint via Cleerly TM's CCTA image analysis pipeline. The mean change in total coronary plaque volume (mm³), as measured by coronary computed tomography angiography (CCTA) using the Cleerly™ image analysis pipeline, from baseline to 12 months will be calculated for each participant and compared between study arms.
Time frame: 12 months
Major adverse cardiovascular events at 12 months
Major adverse cardiovascular events between 0 and 12 months will be noted to determine if there is a difference in major adverse cardiovascular events (MACE) rates between the usual care arm versus the aggressive lipid lowering arm.
Time frame: 12 months
Change in the Proportion of Calcified Plaque Volume from Baseline to 12 Months
Each participant will have proportion of calcified plaque volume measured prior to randomization and at the 12-month timepoint via Cleerly TM's CCTA image analysis pipeline. The difference between these two timepoints in each participant will be calculated to determine if there is a significant difference between proportion of calcified plaque volume changes in the usual care arm versus the aggressive lipid lowering arm.
Time frame: 12 months
Change in Size of the Largest Plaque from Baseline to 12 Months
Each participant will have the size of the largest plaque (by volume) measured prior to randomization and at the 12-month timepoint via Cleerly TM's CCTA image analysis pipeline. The difference between these two timepoints in each participant will be calculated to determine if there is a significant difference between largest plaque volume changes in the usual care arm versus the aggressive lipid lowering arm.
Time frame: 12 months
Started Oct 2026 (actual). Primary completion is estimated for Dec 2027, 14 months after the start.
Of 220 non-industry interventional studies with no phase under Melanoma, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 62. This study's planned 14 months is below that.
Counting every sponsor, half of 228 studies reached it within 38 months; a quarter within 20 and three quarters within 62.
Start moved once since we started tracking on Sep 25, 2026: Dec 2026 → Oct 2026, on Oct 22, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Statins · Ezetimibe · PCSK9 Inhibitor
University of Colorado, Denver →